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Abstract Chronic granulomatous disease (CGD) is an
uncommon congenital immunodeﬁciency seen approxi-
mately in 1 of 250,000 individuals. It is caused by a
profound defect in a burst of oxygen consumption that
normally accompanies phagocytosis in all myeloid cells
(neutrophils, eosinophils, monocytes, and macrophages).
This ‘‘respiratory burst’’ involves the catalytic conversion
of molecular oxygen to the oxygen free-radical superoxide,
which in turn gives rise to hydrogen peroxide, hypochlo-
rous acid, and hydroxyl radicals. These oxygen derivatives
play a critical role in the killing of pathogenic bacteria and
fungi. As a result of the failure to activate the respiratory
burst in their phagocytes, the majority of CGD patients
suffer from severe recurrent infections and rather unex-
plained prolonged inﬂammatory reactions that may result
in granulomatous lesions. Both may cause severe organ
dysfunction depending on the tissues involved. Preventive
measures as well as rapid (invasive) diagnostic procedures
are required to successfully treat CGD. Hematopoietic stem
cell transplantation may be a serious option in some of the
patients.
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Background
Chronic granulomatous disease (CGD) is a rare genetic
disorder caused by a defective NADPH oxidase enzyme
complex [1, 2]. This complex enzyme is responsible for the
burst of oxygen consumption (respiratory burst), which is
associated with phagocytosis by professional phagocytes,
i.e., neutrophils, eosinophils, monocytes, and macrophages.
The enzyme reduces oxygen, giving rise to superoxide
(O2
-) and subsequent reactive oxygen species, which
contribute to the killing of phagocytized microorganisms.
In the majority of CGD patients, the defective NADPH
oxidase is responsible for an inadequate anti-microbial
response, particularly to fungi, yeasts, and several bacterial
species such as Staphylococcus species, Gram-negative
bacteria such as Escherichia coli, nontyphoid Salmonella
species, Klebsiella pneumoniae, and more rare species such
as Burkholderia cepacia or actinomycosis species like
Nocardia asteroids [2, 3].
The organs affected most are the lungs, skin, gastro-
intestinal tract, lymph nodes, and the liver. Pneumonia is a
major complication that occurs, followed by lymphadeni-
tis, infectious dermatitis, and the formation of abscesses.
Although this points to underlying microbial infections,
surprisingly, at most clinical episodes, no causative path-
ogen can be isolated.
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123The formation of granulomas is the other key feature in
CGD, hence its name chronic granulomatous disease [1–3].
Granulomas are highly dynamic structures that, at least ini-
tially, center on the micro-organism or cells containing the
intracellular micro-organism and at its border consist of a
cellular barrier [4]. The formation of granuloma is particu-
larly manifest in conditions with an inadequate anti-
microbial defense, which may relate to the causative
pathogen and/or to the condition of the host. In that respect,
granuloma may be viewed as a means to contain persisting
microorganismsandtosecludethesefromthehost’simmune
response. In CGD, the granulomas found are often sterile,
indicating that the presence of granuloma does not appear to
require the continued presence of microorganisms.
The granulomatous lesions can manifest themselves as
obstruction in the gut, urinary tract, or pulmonary tree, but
also result in a bleeding colitis with a clear failure to thrive.
These two clinical manifestations, infection and
inﬂammation, make the disease difﬁcult to treat. Early
diagnosis is beneﬁcial to the patient because of prophy-
lactic measures, but also when a disease episodes is at
stake, early diagnostic procedures must be entertained to
have a clue on what to do in clinical terms.
Genetics
The clinical presentation of CGD varies between patients,
ranging from early to late in life and from mild to fatal [3].
At least some of this variation in presentation appears to be
related to the underlying genetic defect. Mutations have
been described for ﬁve subunits of the NADPH oxidase,
i.e., gp91
phox, p47
phox, and much more seldom in p67
phox,
p22
phox, and p40
phox [2, 3, 5].
CYBB, the gene encoding the large gp91
phox subunit of
the transmembrane component cytochrome b558 of the
NADPH oxidase complex, is localized on the X-chromo-
some. Genetic defects in CYBB are responsible for the
majority of patients, most often affecting males. All other
mutations are autosomal, which appear associated with a
milder presentation as reﬂected by a higher median age at
death and mean survival time and found among males and
females equally [1, 5].
Biochemistry
A number of molecular processes involved in NADPH
oxidase activation and regulation are known in some detail
[1] and the current working model is schematically shown
in Fig. 1. The catalytic core of NADPH oxidase consists of
cytochrome b558, a heterodimeric membrane protein with
subunits gp91
phox and p22
phox. The gp91
phox subunit (also
called Nox2) is a ﬂavohemoprotein containing all the cat-
alytically active prosthetic groups. The small subunit
p22
phox is a stabilizing protein for gp91
phox and a docking
site for cytosolic proteins that are indispensable for in vivo
NADPH oxidase activation. The architecture of the
NADPH oxidase (i.e., the separation between membrane-
bound and cytosolic subunits) allows its activity to be
tightly regulated.
Regulation is crucial, since accidental or excessive
production of ROS may lead to, for example, inﬂammatory
tissue injury, carcinogenesis, and atherosclerosis. Several
regulatory pathways exist in the onset and shutdown of
NADPH oxidase activity, involving different intracellular
signaling cascades. Phosphorylation of the cytosolic sub-
units p47
phox, p67
phox, and p40
phox by protein kinases and
the generation of lipid second messengers such as arachi-
donic acid, phosphatidic acid, and diacylglycerol by
phospholipases are the two most important signaling
mechanisms in this respect. Additionally, the small GTPase
Rac2 also has a profound inﬂuence on the assembly of a
functional NADPH oxidase in neutrophils, since a mutation
in the GTP-binding site of Rac2 (as found in a patient) [6]
results in a lack of NADPH oxidase activity. However, the
exact role Rac2 plays in activation and regulation is still
under debate [7].
Pathophysiology of CGD
The molecular defects in CGD are known, but how this
leads to the resulting pathophysiology is not well under-
stood. The key features in the pathophysiology of CGD are
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Fig. 1 NADPH oxidase enzyme complex in neutrophils. Upon
cellular activation, an active enzyme complex of proteins is formed,
consisting of the membrane-associated cytochrome b558 and the
cytosolic components p40
phox, p47
phox, p67
phox. The enzymatic
activity of this protein complex—and only as a complex—is able to
generate large amounts of superoxide
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123the exaggerated inﬂammatory responses and the formation
of granuloma. The exaggerated inﬂammatory responses in
CGD may in part be explained by insufﬁcient clearance of
the causative microorganisms. Frequently though, inﬂamed
sites are sterile, indicating that this microbial persistence
may not be the only explanation. The ﬁrst experimental
data indicative of an exaggerated inﬂammatory response in
CGD independent of an infectious agent came from a study
in patients [8], clinical observations, and subsequently
supported by experimental animal studies using gp91
phox
and p47
phox knock-out mice [9, 10].
The hyperinﬂammatory reactivity of the host immune
system was extended in in vitro studies showing that CGD
phagocytes display exaggerated inﬂammatory mediator
responses to various stimuli [11–13]. The absence of ROS
in CGD phagocytes resulted in exaggerated TNF-a pro-
duction [13] and inﬂammasome activity which—under
certain conditions—may be held responsible for the IL-1b
production in CGD [14–16].
Granuloma formation and immune reactivity
Recent studies have brought more insight into the structure
of granuloma, even though the involvement of the various
cell types in a granuloma may differ between tissues and
among diseases.
Expression of the enzyme indoleamine 2,3-dioxygenase
(IDO) at the border of granulomata is a common feature
[17]. IDO, at the expense of superoxide, degrades the
amino acid L-tryptophan to L-kynurenine, which is catab-
olized further (Fig. 2)[ 18].
L-tryptophan is an essential amino acid for most
microbial pathogens, and thus its depletion halts bacterial
growth and viral replication [19, 20]. In addition, low
concentrations of L-tryptophan and enhanced concentra-
tions of L-kynurenine and some of its metabolites halt cell-
cycle progression and promote apoptosis of T lymphocytes,
thereby diminishing the initiation of an immune response
[21, 22]. Therefore, IDO expression in granulomata may
halt bacterial growth and dampen T cell responses towards
the causative pathogen.
Interferon-c (IFN-c) is the primary inducer of IDO
expression. TNF-a released upon infection by dendritic
cells and macrophages is able to induce the IFN-c that in its
turn can induce IDO activity in granuloma [17].
Indoleamine 2,3-dioxygenase and CGD
Aspergillus infection has recently been studied in a CGD
mouse model, and activity of IDO was shown to be crucial
for the survival of Aspergillus infection [23]. IDO converts
L-tryptophan into L-kynurenine but requires superoxide as a
cofactor for its activity. Secreted L-kynurenine subse-
quently acts as an anti-inﬂammatory agent, by mechanisms
that are not completely understood but have been shown to
induce cell death in pro-inﬂammatory cd T cell subsets
producing IL-17 [23]. Romani et al. thus concluded that
hyperinﬂammation caused a lethal outcome for CGD mice
upon challenge with Aspergillus, rather than a defective
clearance itself, as was previously suggested in CGD
patients with an overwhelming pulmonary aspergillosis
[24]. This seems plausible in view of a large body of evi-
dence showing that CGD patients often display
exaggerated immune responses against immunologic
challenges [13], and granulomas have been shown to
develop in the absence of any detectable pathogen, even
after wound sterilization or after injection of heat-inacti-
vated pathogens [9].
Romani and coworkers underscore their conclusion by
demonstrating that CGD mice, which all died upon
Aspergillus challenge, survive this infection when treated
with the IDO product L-kynurenine in combination with
IFN-c. In turn, wild-type mice, which normally survive this
challenge, no longer overcome Aspergillus infection when
treated with the IDO-inhibitor 1-MT [23]. Although the
speciﬁcity of the challenge and the background of the CGD
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Fig. 2 Interferon-inducedtryptophancatabolismviaIDO.Interferon-c
is a major inducer of IDO expression and possibly of other enzymes
involvedinthecatabolismoftryptophan,thekynureninepathway.IDO
is the rate-limiting enzyme in the kynurenine pathway; hence,
regulating IDO-dependent counter-inﬂammatory homeostatic
responsesinpotentiallyharmfulinﬂammation,andrequiressuperoxide
for its activity. Tryptophan catabolism leads to tryptophan starvation
and the production of immunoregulatory kynurenine metabolites, the
combined effects of which result in an arrest of lymphocyte prolifer-
ation, induction of apoptosis and reversible impairment of T cell
activity, as well as in the induction of various mediators, such as IL-6,
IL-8, and IL-10
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123mouse strain are subject for debate, the above-mentioned
relevant ﬁndings have certainly opened a ﬁeld of research
at the boundary of innate and adaptive immunity and the
complex interplay between the two defense systems.
There are a number of experimental ﬁndings that also
contrast with those reported by Romani’s group. First of
all, Murray et al. [25] showed that IFN-c-exposed mono-
cytes and monocyte-derived macrophages from a CGD
patient degraded tryptophan just like cells from a healthy
individual. This suggests that superoxide from the NADPH
oxidase is not the essential cofactor for IDO activity. In
fact, there are several studies that suggest that IDO may
acquire its reducing equivalents from prosthetic groups
such as heme and ﬂavin [26, 27], unrelated to the NADPH
oxidase enzyme.
Another major aspect of the study by Romani et al. is
that L-kynurenine is not accumulating in CGD mice and
L-kynurenine suppletion restores the defective down-regu-
lation of the inﬂammatory cd T cells. IDO is the rate-
limiting enzyme in the kynurenine cascade, meaning that
the IDO-generated L-kynurenine is usually very quickly
catabolized. Thus, an alternative explanation for the ﬁnd-
ings by Romani et al. could be that L-kynurenine is more
rapidly degraded in CGD patients than in healthy individ-
uals. If so, the lack of L-kynurenine can not be taken as a
measure of defective IDO activity. In a CGD cohort study,
these issues were addressed most recently by the group of
Malech, who demonstrated that IFN-c induces normal
levels of L-kynurenine in cultures of monocytes, dendritic
cells, and PMN from gp91
phox and p47
phox-deﬁcient human
CGD patients. L-kynurenine accumulation was dose- and
time-dependent, as was that of the downstream metabolite
3-OH anthranilic acid. Furthermore, urinary and serum
levels of L-kynurenine and a variety of other tryptophan
metabolites were elevated rather than suppressed in CGD
donors [28].
As explicitly stated, the data in CGD patients only dem-
onstrated the lack of abnormal IDO activity in blood cells,
but little is known about tissue activity or localization. In
preliminary immunohistochemical studies, a marked
expression of IDO was noticed at the rim of granulomata in
lung tissue from CGD patients (Fig. 3). Infection was
excluded in these pathological patient-derived tissue sam-
ples. Neutrophils were found predominantly in the center of
the granulomata, T cells both in the center and outside of the
granulomata, whereas macrophages particularly localized at
the border of the granulomata. These macrophages expres-
sed most if not all of the IDO protein detected in these tissue
samples. In particular, the neutrophils showed virtually no
IDO protein expression, in contrast to the ﬁndings in the
mouse model as reported by Romani et al. [23].
It was noted that the IDO expression in CGD tissue is
much more abundant than that in granulomatous tissue
from patients with sarcoidosis and tuberculosis (Lutter, van
der Loos, unpublished). Since IDO activity induces apop-
tosis, apoptotic cells in the vicinity of IDO expression in
CGD tissue can be taken as an indicator of IDO activity.
Indeed, marked numbers of apoptotic (active caspase-3
Fig. 3 Triple staining of CGD granuloma in lung tissue. a (left):
neutrophils (MPO; red), IDO (blue), activated caspase 3 (apoptosis,
green); b (middle) as in A for macrophages (CD68; red), c (right)a s
in a for T cells (CD3; in red)
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123positive) cells were found, predominantly in the center and
border of the granulomata and consisting of neutrophils, T
cells, and macrophages. These ﬁndings—taken together
with the ﬁndings on L-kynurenine and IDO activity in CGD
patients recently published by Malech et al. [28]—suggest
that the general activity may be normal, while locally
induced IDO activity may still be present in the affected
tissues. It is unclear whether this markedly increased yet
localized IDO activity in CGD patients directly contributes
to the clinical manifestations of hyperinﬂammation in
CGD. In a previous study by one of us, it was shown that
IDO activity may lead to the increased production of
inﬂammatory mediators by airway epithelial cells, which
will lead to an exaggerated inﬂammatory reaction [29]. In
an experimental pneumonia model, a similarly IDO-med-
iated enhanced production of both TNF-a and IL-10 was
found [30]. IL-10 is known to inhibit neutrophil function
and thus contribute to the increased bacterial load observed
in this lung model. Together, this could indicate that an
enhanced IDO activity in granulomata may enhance the
recruitment of inﬂammatory cells and at the same time
prevent their functioning, which may lead to a prolongation
of the inﬂammatory response.
T lymphocytes in inﬂammation and neutrophilia
Discoveries made over the past two decades have markedly
changed the way we assume immunological processes are
being regulated. Not the least of these was the identiﬁca-
tion and cloning of several new cytokines, including IL-17
[31]. These discoveries provided the impetus to explore
outside the T helper 1 (Th1)-Th2 cell paradigm in search of
answers to explain the effector T cell responses that occur
independently of known Th1 and Th2 cell-signaling path-
ways. It was clear that a strong T cell-dependent response
can occur even in the absence of the Th1 cell-promoting
factors IFN-c, signal transducer and activator of tran-
scription-1 (STAT1) and STAT4 or the Th2 cell promoting
factors IL-4, STAT6 and GATA-binding protein-3
(GATA3). Through the study of the role of IL-23 in
autoimmunity, it was discovered that an alternative T cell
subset can promote chronic inﬂammation and tissue dam-
age [32]. The Th17 cell was identiﬁed as a cell, in which
IL-6-STAT3 activation of the transcriptional regulator
retinoic acid receptor-related orphan receptor-ct (RORct)
controls the lineage fate of IL-17, IL-21-, and IL-22-pro-
ducing T cells (known as Th17 cells), that are highly
responsive to IL-1-receptor-I (IL-1R1) and IL-23R sig-
naling [32].
The adaptive Th17 cell pathway was inadequate to
explain the early IL-17-mediated immune responses that
have crucial roles during stress responses and host defense.
The IL-17-mediated immune pathway is induced within
hours following epithelial cell injury or activation of pat-
tern-recognition receptors (PRRs), which is not enough
time for the development of Th17 cells. IL-17 produced
within 4–8 h after microbial infection was shown to
enhance neutrophil chemotaxis by promoting IL-6, G-CSF,
and CXC-chemokine ligand-8 (CXCL8; also known as
IL-8) production and to trigger rapid, nonspeciﬁc immunity
to infectious agents [33].
A hallmark of innate immunity is its rapid response to
pathogens. Innate IL-17-producing cells can induce epi-
thelial cell secretion of granulopoietic factors such as
G-CSF, which recruit large numbers of neutrophils crucial
for effective and rapid control of bacterial and fungal
pathogens. IL-17 also synergizes with other cytokines, such
as IL-1, IL-6, and TNF-a that promote activation of tissue
inﬁltrating neutrophils to effectively eliminate extracellular
pathogens, such as Klebsiella pneumoniae, Staphylococcus
aureus, and Candida albicans. Several innate cell subsets
could cooperate to promote this immediate IL-17-mediated
response. In the lung, skin, liver, and gut, the cd T cell
subset has been implicated as a primary source of early IL-
17 production in several in vivo models of infection. Initial
studies looked at extracellular pathogens that target the
lungs, such as K. pneumoniae, and showed that IL-23 was a
main stimulator of innate IL-17 production [34].
It is important to note that innate IL-17 populations not
only interact with pathogens during infection but also
interact with the commensal ﬂora to maintain mucosal
homeostasis. IL-17 also has an important role in main-
taining mucosal barrier integrity both during homeostasis
and pathogenic insults. One way IL-17 can preserve tissue
integrity is by enhancing synthesis of tight junction pro-
teins, such as claudin. These tight-junction proteins form
interconnecting ultrastructures between epithelial cells to
keep out gut luminal contents and commensal organisms.
Another mechanism for the protective effects of IL-17 is
the induction of antimicrobial agents such as b-defensins,
regenerating (ReG) proteins, S100 proteins, lipocalins, and
lactoferrins. These microbicidal agents are predominantly
produced by epithelial cells, as well as neutrophils and
macrophages that constitutively express IL-17R. It is
notable that IL-17 often works cooperatively with IL-22. In
the airways, IL-17 and IL-22 have been shown to work
together to promote the secretion of human b-defensin-2,
b-defensin-3 and calgranulin by bronchial epithelial cells,
essential for the killing of bacterial and fungal pathogens
[35], a defect that may explain the recurrent skin and lung
infections in the autosomal-dominant Hyper-IgE syn-
drome, as caused by mutations in STAT3.
Also in the gut mucosa, IL-17 and IL-22 may have
synergistic effects on the induction of antimicrobial pro-
teins such as ReG3c by gastrointestinal epithelial cells
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control of pathogens and limits dissemination of com-
mensal bacteria that could penetrate a disrupted epithelial
barrier. These innate and adaptive memory immune cells
can be assumed to act in concert to produce a basal level of
IL-17 and IL-22, which then maintain a constitutive level
of antimicrobial proteins [36].
IL-17-mediated activity during infections in CGD
IL-17 augmented inﬂammation, but, paradoxically,
impaired neutrophil antifungal host defense in mice [37].
As mentioned earlier, Romani et al. demonstrated that IDO-
mediated L-tryptophan metabolism along the kynurenine
pathway is defective in CGD mice. As a consequence,
unrestrained cd T cell and ab Th17 expansion, defective
regulatory Treg activity, and acute inﬂammatory lung injury
leading to mortality occurred in CGD mice when chal-
lenged with intratracheal Aspergillus fumigatus [23].
Although complete protection from invasive fungal disease
and reversal of the hyperinﬂammatory phenotype were
achieved by recombinant IFN-c and administration of a
natural L-kynurenine distal to the IDO blockade was sug-
gested, beneﬁcial effects in this infection model were also
induced by IL-17 neutralization or depletion of cd T cells
(which produce IL-17) in CGD mice [23, 38]. Similar to
Aspergillus challenge, intratracheal zymosan (a sterile
fungal cell wall constituent that ligates Toll-like receptor 2
and dectin-1), caused dramatically augmented lung
inﬂammation and IL-17 production and diminished Treg
responses in CGD compared to wild-type mice, emphasiz-
ing the intrinsic regulatory role of the NADPH oxidase on
inﬂammation [39]. George-Chandy et al. recently showed
that gp91
phox-negative dendritic cells (DCs) enhance
induction of both Th17 and Th1 responses in vitro com-
pared to wild-type DCs [40]. T cell development was
dependent exclusively on the NADPH oxidase status of the
activating DCs rather than the responding T cells. To date,
we did not detect a defect in Th17 development in CGD
patients, making alternative explanations well possible.
Inﬂammatory and regulatory T cells
Tregs and IL-17-producing T cells mediate opposing
responses. IL-17 stimulates production of G-CSF, GM-
CSF, TNF-a, and chemokines that regulate myelopoiesis
and neutrophil recruitment to inﬂammatory sites. The IL-
23/IL-17 axis (IL-23 expands Th17 cells) mediates several
experimental autoimmune disorders, including colitis,
collagen-induced arthritis, and experimental autoimmune
encephalomyelitis, and is a promising target for drug
development. T cells producing IL-17, which is known to
drive chronic inﬂammation, are held in check by regulatory
T cells. Although a potential role of IL-17-producing cells
will very well be possible, this mechanism requires further
conﬁrmation in human CGD patients. On the other hand,
Montagnoli et al. [38] previously showed that naturally
occurring Tregs are recruited early in the inﬂammatory
response to Aspergillus in wild-type mice, and are capable
of suppressing inﬂammation.
Apart from IDO activity and localization of Th17
reactivity, a regulatory defect in the Treg-mediated control
of the adaptive immune system may be present in CGD.
The role of Tregs in the exaggerated innate immune
reactivity loop in CGD was suggested by previous studies
in mice and rats with mutant Ncf1 alleles (encoding
p47
phox) associated with defective ROS production. Due to
a less functional NADPH oxidase complex, these animals
are more susceptible to develop autoimmune diseases as
compared to littermates with normal ROS production [41,
42]. This is in line with the observation that patients with
CGD who are unable to produce ROS have a higher inci-
dence of autoimmune diseases such as granulomatous
colitis or Crohn’s-like disease (CD), rheumatoid arthritis
(RA), or systemic lupus erythematosus (SLE) [43, 44].
In the rat model for CGD, the T cells were responsible
for mediating the higher susceptibility to pristane-induced
arthritis [41, 45]. However, T cells themselves do not
express p47
phox and do not produce ROS via NADPH
oxidase [46]. Instead, the antigen-presenting cells were
involved in aberrant adaptive immune reactivity under
these conditions. Macrophages are far more efﬁcient in
producing ROS as compared to B cells and dendritic cells
(DC) [47]. A transgenic mouse was developed that
expressed functional p47
phox in macrophages only, on a
p47
phox-mutated background. These mice were equally
protected against collagen-induced arthritis as wild-type
littermates, indicating that macrophage-derived ROS are
sufﬁcient to prevent the induction of unwanted T cell
reactivity [47].
Regulatory T cells (Tregs) can suppress activation and
proliferation of effector T cells and thereby diminish most
immune responses. Autoimmunity can therefore be the
result of a defective Treg system [48] and successful
treatment of autoimmune disease with Tregs has been
reported in mouse models [49, 50]. Reasoning along these
lines, Treg induction via ROS can be mediated via mac-
rophages, as was reported before [51]. In collaboration,
Keldeman et al. indeed observed that such a mechanism of
ROS-dependent Treg induction seems to be relevant to
CGD. Macrophage-derived ROS could induce Tregs under
normal conditions. In contrast, macrophages from CGD
patients were signiﬁcantly less efﬁcient in inducing Tregs
(Keldeman et al. PNAS 2011). Thus, macrophages
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regulation, a regulatory loop that seems to be impaired in
CGD. Previously it has been found that T cell suppression
by Tregs induced by anti-inﬂammatory macrophages is
dependent on membrane-bound TGF-b [51]. A role for
ROS to activate TGF-b was suggested before [52, 53],
and this may subsequently determine the induction of
Tregs.
In sum, when macrophages prevent T cell reactivity by
producing ROS, the activation signal needs to overcome a
certain threshold level for T cell activation and this fail-
safe mechanism may thus prevent unwanted inﬂammation
and autoimmunity.
Conclusions
To date, the abundant presence of results in experimental
mouse models as well as in human CGD patients indicate
that the NADPH oxidase complex is able to restrain
inﬂammation by modulating redox-sensitive innate immune
pathways. When challenged with either intratracheal
zymosan or LPS, NADPH oxidase-deﬁcient (CGD p47
phox
and gp91
phox-deﬁcient mice develop exaggerated and pro-
gressive lung inﬂammation, which is paralleled by
augmented NF-jB activation and elevated downstream pro-
inﬂammatory cytokines (TNF-a, IL-17, and G-CSF) in
comparison to wild-type mice [39]. Replacement of func-
tional NADPH oxidase in bone marrow-derived cells
restored the normal lung inﬂammatory response in experi-
mental models. These recent studies further demonstrated
that in the absence of a functional NADPH oxidase system,
the yeast capsular zymosan particles fail to activate Nrf2, a
key redox-sensitive anti-inﬂammatory regulator. A small
chemical compound, the triterpenoid CDDO-Im, activated
Nrf2 independently of NADPH oxidase and reduced the
zymosan-induced lung inﬂammation in CGD mice. Con-
sistent with these ﬁndings, zymosan-treated peripheral
blood mononuclear cells from human X-linked CGD
patients also showed impaired Nrf2 activity and increased
NF-jB activation.
Whether these two observations in mice and human
macrophages are directly linked and to which extent these
data relate to T cell-mediated regulation of the hyperin-
ﬂammatory reactivity in CGD patients as discussed above,
remains to be studied in greater detail. Apart from IL-17,
the role of TGF-b induction, activation and downregulation
may be relevant to the outcome of inﬂammation and sub-
sequent risk of proceeding tissue ﬁbrosis, as can be
observed in chronic disease in CGD patients.
Together these studies support a model in which
NADPH oxidase-dependent, redox-mediated signaling is
critical for termination of lung inﬂammation and suggest
new potential therapeutic targets for CGD.
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